Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabplagem in Metastatic Pancreatic Cancer
NCT01893801Phase 2Completed
- Sponsor
- Pancreatic Cancer Research Team
- Start
- May 2013
- Primary completion
- Apr 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, Cisplatin micelle injection (HA132) and gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Pancreatic Cancer Research Team. Primary endpoint: Complete Response Rate at 1 year. Started May 2013; status: completed.
02
Drugs
paclitaxelCisplatin micelle injection (HA132)gemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01893801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893801.